The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Launched by FUJIAN CANCER HOSPITAL · Dec 6, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed adenocarcinoma of the rectum；
• • The clinical stage evaluated by MRI was T3-4 and/or N+ and M1a(only liver metastasis)；
• • ECOG PS 0-2；
• • CHild Pugh A；
• • Estimated survival ≥3 months;
• • Women of childbearing age should comply with contraceptive measures if pregnancy test is negative;
• • Adequate organ and bone marrow functions, ecg, blood, biochemical and other basic tests are not contraindications of chemotherapy;
• • Adherence to scheduled visits, treatment plans, laboratory tests, and other study procedures Willingness and ability.
• Exclusion Criteria:
• • Pregnant or lactating women;
• • No previous antitumor therapy；
• • No previous liver local therapy；
• • No contraception during the reproductive period;
• • patients known to have a history of allergy to any study drug, similar drug or excipient;
• • Patients with risk of massive gastrointestinal bleeding or gastrointestinal obstruction;
• • Patients with a history of thromboembolism, except those caused by PICC;
• • Patients with active infection;
• • Other conditions that the investigator determines are not suitable for inclusion in the study.